Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells - PubMed (original) (raw)
. 1998 May 12;95(10):5690-3.
doi: 10.1073/pnas.95.10.5690.
J Cui, Y Koezuka, I Toura, Y Kaneko, H Sato, E Kondo, M Harada, H Koseki, T Nakayama, Y Tanaka, M Taniguchi
Affiliations
- PMID: 9576945
- PMCID: PMC20440
- DOI: 10.1073/pnas.95.10.5690
Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells
T Kawano et al. Proc Natl Acad Sci U S A. 1998.
Abstract
We have recently identified alpha-galactosylceramide (alpha-GalCer) as a specific ligand for an invariant Valpha14/Vbeta8.2 T cell receptor exclusively expressed on the majority of Valpha14 NKT cells, a novel subset of lymphocytes. Here, we report that alpha-GalCer selectively activates Valpha14 NKT cells resulting in prevention of tumor metastasis. The effector mechanisms of the ligand-activated Valpha14 NKT cells seem to be mediated by natural killer (NK)-like nonspecific cytotoxicity. Indeed, the cytotoxic index obtained by alpha-GalCer-activated Valpha14 NKT cells was reduced by the addition of cold target tumor cells or by treatment with concanamycin A, which inhibits activation and secretion of perforin, but not by mAbs against molecules involved in the NKT cell recognition and conventional cytotoxicity, such as CD1d, Vbeta8, NK1. 1, Ly49C, Fas, or Fas ligand. These results suggest that the ligand-activated Valpha14 NKT cells kill tumor cells directly through a CD1d/Valpha14 T cell receptor-independent, NK-like mechanism.
Figures
Figure 1
Inhibition of liver metastasis of B16 melanoma cells by in vivo treatment with α-GalCer. (A) Melanoma antigens in metastasized livers measured by RIA using 125I-labeled M2590 mAb. B16 melanoma cells (3 × 106 per mouse) were inoculated in the spleen of wild-type (Jα281+/+), Vα14 NKT-deficient (Jα281−/−), and Vα14 NKT (RAG−/−/Vα14tg Vβ8.2tg) mice, followed by intraperitoneal injection with either α-GalCer (100 μg/kg) or vehicle on days 1, 5, and 9. The mice were sacrificed and examined on day 14. Each group consisted of three mice. The data are expressed as a mean cpm value of triplicate samples with standard errors. (B) Photographic views of metastasized livers from mice treated with α-GalCer or vehicle.
Figure 2
Cytotoxicity of spleen cells from Vα14 NKT mice after in vivo treatment with α-GalCer. Vα14 NKT mice were injected intraperitoneally with either α-GalCer (100 μg/kg) or vehicle, and 24 hr later spleen cells were used as effector cells for cytotoxic assay on B16 melanoma cells at indicated effector/target ratios.
Figure 3
Effector mechanism of α-GalCer-activated Vα14 NKT cells. (A) α-GalCer-activated Vα14 NKT cells were incubated with 51Cr-labeled B16 melanoma cells in the presence of various numbers of unlabeled tumor cells (B16 or EL-4) as cold targets. Cytotoxic assays were performed at an E/T ratio of 25:1. (B) Effect of CMA treatment on α-GalCer-activated Vα14 NKT cells. α-GalCer-activated Vα14 NKT cells were treated with indicated doses of CMA for 2 hr, and their cytotoxic activity was assessed on 51Cr-labeled B16 melanoma at an E/T ratio of 50:1.
Figure 4
Molecular requirements in the effector phase of cytotoxic function of α-GalCer-activated Vα14 NKT cells. (A) Effects of various mAbs on Vα14 NKT cell-mediated cytotoxicity. Fifty micrograms per ml of the indicated mAbs were added to the cytotoxic assays. (B) Cytotoxic activity of Vα14 NKT cells on α-GalCer-pulsed class I-deficient RMA-S cells and their CD1d-transfectants. RMA-S and RMA-S-CD1.1 cells were pulsed with α-GalCer and used as target cells. The data are expressed as a mean value of triplicate cultures with standard deviations.
Figure 5
Cytotoxicity of NK and Vα14 NKT cells against FBL-3 erythroleukemia cells. (A) Fluorescence-activated cell sorter profiles of FBL-3. Cells were stained with anti-H-2Kb (AF6–88.5) or H-2Db (KH95) antibodies. Isotype-matched antibody was used as a negative control. (B) Cytotoxic activity. Freshly isolated spleen cells from Vα14 NKT mice (•) or RAG−/− (NK) mice (○) were assayed for their cytotoxicity by the 4-hr 51Cr-release assay on FBL-3 tumor cells expressing MHC class I molecules on the cell surface.
Similar articles
- Involvement of decidual Valpha14 NKT cells in abortion.
Ito K, Karasawa M, Kawano T, Akasaka T, Koseki H, Akutsu Y, Kondo E, Sekiya S, Sekikawa K, Harada M, Yamashita M, Nakayama T, Taniguchi M. Ito K, et al. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):740-4. doi: 10.1073/pnas.97.2.740. Proc Natl Acad Sci U S A. 2000. PMID: 10639149 Free PMC article. - Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S, Juji T. Nicol A, et al. Immunology. 2000 Feb;99(2):229-34. doi: 10.1046/j.1365-2567.2000.00952.x. Immunology. 2000. PMID: 10692041 Free PMC article. - DOCK2 is required in T cell precursors for development of Valpha14 NK T cells.
Kunisaki Y, Tanaka Y, Sanui T, Inayoshi A, Noda M, Nakayama T, Harada M, Taniguchi M, Sasazuki T, Fukui Y. Kunisaki Y, et al. J Immunol. 2006 Apr 15;176(8):4640-5. doi: 10.4049/jimmunol.176.8.4640. J Immunol. 2006. PMID: 16585555 - Valpha14 NKT cell-mediated anti-tumor responses and their clinical application.
Seino K, Fujii S, Harada M, Motohashi S, Nakayama T, Fujisawa T, Taniguchi M. Seino K, et al. Springer Semin Immunopathol. 2005 Jun;27(1):65-74. doi: 10.1007/s00281-004-0194-y. Epub 2005 Jan 14. Springer Semin Immunopathol. 2005. PMID: 15650847 Review. - Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S, Shimizu K, Hemmi H, Steinman RM. Fujii S, et al. Immunol Rev. 2007 Dec;220:183-98. doi: 10.1111/j.1600-065X.2007.00561.x. Immunol Rev. 2007. PMID: 17979847 Review.
Cited by
- Chemical synthesis and immunological evaluation of cancer vaccines based on ganglioside antigens and α-galactosylceramide.
Romanò C, Jiang H, Tahvili S, Wei P, Keiding UB, Clergeaud G, Skovbakke SL, Blomberg AL, Hafkenscheid L, Henriksen JR, Andresen TL, Goletz S, Hansen AE, Christensen D, Clausen MH. Romanò C, et al. RSC Med Chem. 2024 Jun 21;15(8):2718-2728. doi: 10.1039/d4md00387j. eCollection 2024 Aug 14. RSC Med Chem. 2024. PMID: 39149099 Free PMC article. - Human CD4+ iNKT cell adoptive immunotherapy induces anti-tumour responses against CD1d-negative EBV-driven B lymphoma.
Baiu DC, Sharma A, Schehr JL, Basu J, Smith KA, Ohashi M, Johannsen EC, Kenney SC, Gumperz JE. Baiu DC, et al. Immunology. 2024 Aug;172(4):627-640. doi: 10.1111/imm.13799. Epub 2024 May 13. Immunology. 2024. PMID: 38736328 - T Cell Receptor-Engaging Monoclonal Antibodies Mobilize the Anti-Tumor Functions of Invariant Natural Killer T Cells.
Das R. Das R. Crit Rev Oncog. 2024;29(1):69-81. doi: 10.1615/CritRevOncog.2023049947. Crit Rev Oncog. 2024. PMID: 38421715 - Cytotoxic immune cells do not affect TDP-43 and p62 sarcoplasmic aggregation but influence TDP-43 localisation.
McCord B, Day RM. McCord B, et al. Sci Rep. 2023 Sep 23;13(1):15935. doi: 10.1038/s41598-023-42824-5. Sci Rep. 2023. PMID: 37741931 Free PMC article. - Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy.
Aoki T, Motohashi S, Koseki H. Aoki T, et al. Inflamm Regen. 2023 May 12;43(1):27. doi: 10.1186/s41232-023-00275-5. Inflamm Regen. 2023. PMID: 37170375 Free PMC article. Review.
References
- Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M. Int Immunol. 1995;7:1157–1161. - PubMed
- Fowlkes B J, Kruisbeek A M, Ton-That H, Weston M A, Coligan J E, Schwartz R H, Pardoll D M. Nature (London) 1987;329:251–254. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous